Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$67.15
+1.0%
$54.53
$43.38
$67.37
$9.09B1.111.17 million shs959,877 shs
Haemonetics Co. stock logo
HAE
Haemonetics
$90.10
-3.3%
$87.25
$70.74
$97.97
$4.73B0.34468,880 shs2.24 million shs
Nevro Corp. stock logo
NVRO
Nevro
$9.81
-1.5%
$12.36
$8.93
$28.42
$360.32M0.96515,738 shs604,732 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$198.97
-0.6%
$213.23
$180.93
$348.67
$7.71B0.57341,802 shs170,696 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$51.39
+4.2%
$36.78
$13.82
$52.51
$3.19B1.11.77 million shs2.05 million shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
+0.40%+5.82%+32.14%+20.99%+17.01%
Haemonetics Co. stock logo
HAE
Haemonetics
-2.22%-4.28%+14.72%+27.25%+11.66%
Nevro Corp. stock logo
NVRO
Nevro
-5.32%+0.91%-17.48%-39.78%-63.60%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.59%-4.06%-1.22%-22.37%-37.16%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+4.43%+11.91%+62.08%+118.71%+66.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.4553 of 5 stars
2.31.00.04.13.83.33.1
Haemonetics Co. stock logo
HAE
Haemonetics
3.9246 of 5 stars
2.31.00.04.32.52.52.5
Nevro Corp. stock logo
NVRO
Nevro
1.5689 of 5 stars
4.03.00.00.00.01.70.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.8752 of 5 stars
4.41.00.03.82.62.53.1
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
3.6398 of 5 stars
2.53.00.04.94.10.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.64
Moderate Buy$68.502.01% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$108.6720.61% Upside
Nevro Corp. stock logo
NVRO
Nevro
1.92
Reduce$19.4698.38% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.70
Moderate Buy$300.6451.10% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.91
Moderate Buy$49.73-3.24% Downside

Current Analyst Ratings

Latest HAE, GMED, TNDM, PEN, and NVRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell$13.50 ➝ $9.00
5/22/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $75.00
5/22/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $55.00
5/22/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$40.00 ➝ $57.00
5/20/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$60.00 ➝ $80.00
5/10/2024
Haemonetics Co. stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$115.00 ➝ $125.00
5/10/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $107.00
5/10/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/9/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$83.00 ➝ $85.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $60.00
5/8/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $63.00
(Data available from 5/22/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.57B5.80$3.66 per share18.37$28.98 per share2.32
Haemonetics Co. stock logo
HAE
Haemonetics
$1.31B3.50$5.66 per share15.91$18.90 per share4.77
Nevro Corp. stock logo
NVRO
Nevro
$425.17M0.85N/AN/A$7.58 per share1.29
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.29$2.79 per share71.24$31.05 per share6.41
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$770.01M4.31N/AN/A$3.76 per share13.67

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$0.64104.9220.541.843.51%8.82%7.06%8/1/2024 (Estimated)
Haemonetics Co. stock logo
HAE
Haemonetics
$117.56M$2.2939.3517.771.738.98%22.25%9.73%8/13/2024 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.29N/AN/AN/A-19.17%-27.48%-13.40%8/6/2024 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3783.9550.762.048.52%7.83%5.91%8/6/2024 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$2.17N/AN/AN/A-18.37%-34.38%-10.91%8/1/2024 (Estimated)

Latest HAE, GMED, TNDM, PEN, and NVRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q4 2024
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88$0.90+$0.02$1.40$329.53 million$343.00 million    
5/7/2024Q1 2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.55$0.72+$0.17$1.49$586.82 million$606.67 million    
5/7/2024Q1 2024
Nevro Corp. stock logo
NVRO
Nevro
-$1.02-$0.70+$0.32-$0.70$97.90 million$101.90 million    
5/7/2024Q1 2024
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42$0.41-$0.01$0.54$274.94 million$278.70 million      
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
2.33
1.29
Haemonetics Co. stock logo
HAE
Haemonetics
0.83
2.56
1.50
Nevro Corp. stock logo
NVRO
Nevro
0.77
7.38
5.57
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.12
3.51
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.43
3.81
3.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.54%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million110.27 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.73 million35.55 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.76 million36.83 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,40064.59 million63.17 millionOptionable

HAE, GMED, TNDM, PEN, and NVRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Tandem Diabetes Care logo

Tandem Diabetes Care

NASDAQ:TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.